A tumor neoantigen load detecting device and a storage medium

Abstract

A tumor neoantigen load detecting device and a storage medium are provided. The detecting device includes a data acquisition unit used for acquiring sequencing data of target capturing zones of tumortissue DNA of a detection subject, control sample DNA, and tumor tissue RNA; a somatic cell mutation detecting unit used for mutation detection and annotation on the sequencing data of the tumor tissue DNA and the control sample DNA to obtain a mutant peptide segment; a fusion gene detecting unit used for subjecting the sequencing data of the tumor tissue RNA to fusion gene detection and annotation to obtain a mutant peptide segment; an HLA typing detection unit used for performing HLA typing on the sequencing data of the target capturing zones of the control sample DNA; an MHC affinity predicting unit used for predicting neoantigen for the mutant peptide segments according to an HLA typing detection result; a TNB calculating unit used for calculating TNB; and a result outputting unit usedfor outputting a TNB detection result. The device and the storage medium can be used for detecting and monitoring the tumor neoantigen load, and predicting curative effects of immune checkpoint inhibitors.

Description

technical field [0001] The invention relates to the technical field of tumor detection, in particular to a tumor neoantigen load detection device and a storage medium. Background technique [0002] Tumors are diseases caused by mutations in the genome. Immune checkpoint inhibitors have opened up a new era of tumor therapy, but due to the lack of suitable clinical molecular markers, PD-1 / PD-L1 (programmed cell death receptor-1, programmed death-1, PD-1; programmed death-1; Cell death ligand-1, programmed cell death ligand 1, PD-L1) drug benefit groups cannot be efficiently screened, and the screening rate is only 20%-30%. Potential clinical molecular markers that have been discovered so far include PD-L1 expression level, tumor neoantigen load, etc. These molecular markers can be used to predict the therapeutic effect of some patients, but there are still cases where they are not applicable. Tumor neoantigen burden (TNB) is an indicator that directly reflects the number of ...

AI Technical Summary

Problems solved by technology

At present, there is no such mature product on the market, and the method of whole exome sequencing is usually used in research, which has the disadvantages of high cost and long cycle, and is not suitable for clinical application

Images